Lessons learned from the failure of clinical studies of TGF-β1 blockade underscore the need for alternative approaches to CKD therapy, as strategies that target a single pathogenic process may result in unexpected negative effects on simultaneously occurring processes [46, 47]. This evidence concerns the gene TGFB1 and chronic kidney disease.